ANN ARBOR, Mich., Oct. 30, 2008 (GLOBE NEWSWIRE) — Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the 30th patient has been treated in the Company’s U.S. Phase IIb RESTORE-CLI clinical trial. This milestone marks the first step toward interim data retrieval from this clinical trial evaluating Aastrom’s Vascular Repair Cells (VRCs) in the treatment of patients suffering from the most severe form of peripheral arterial disease (PAD), critical limb ischemia

Continue reading: Aastrom Announces Achievement of Milestone in U.S. Phase IIb Critical Limb Ischemia Clinical Trial